Relationship between TCGA molecular classification with FIGO grade and stage of endometrial cancer:a meta analysis
Objective To evaluate the relationship between TCGA molecular typing with FIGO grade and clinical stage of endometrial carcinoma.Methods The clinical studies about TCGA molecular typing of endometrial cancer in PubMed,Web of Science,EMBASE,CNKI and Wanfang databases were retrieved by computer.The retrival time was from the establishment of the database to December 2021.The literatures were screened according to the inclusion and exclusion criteria for conducting the data extraction.The RevMan 5.3 and SPSS 21.0 softwares were used for the meta analysis.Results A total of 10 related articles were in-cluded,6 articles in English and 4 articles literatures in Chinese.There were 3 813 cases of endometrial cancer,including 213 cases(5.6%)of POLE mutation type,1 103 cases(28.9%)of MSI-H type,1 954 cases(51.2%)of CN-L type and 543 cases(14.2%)of CN-H type.A total of 10 articles analyzed the relationship between TCGA molecular subgroups and FIGO grade,8 articles analyzed the relationship with the clinical stage,depth of muscular infiltration and lymph node metastasis,9 articles analyzed the relationship with the histological typing and LVSI,and 2 articles analyzed the cytological statistics of peritoneal lavage fluid.In the comparison between FIGO G3 and G1-2 stage,OR of POLE mutant type was 1.46(95%CI 1.06-2.03);OR of MSI-H type was 1.42(95%CI 1.16-1.74);OR of CN-L type was 0.20(95%CI 0.14-0.29);OR of CN-H type was 9.62(95%CI 4.61-16.67).In the comparision between FIGO Ⅱ-Ⅳ and FIGO 1,OR of POLE mutant type was 0.44(95%CI 0.27-0.72);OR of MSI-H type was 1.12(95%CI 0.92-1.37;OR of CN-L type was 0.51(95%CI 0.36-0.74;OR of CN-H type was 2.81(95%CI 2.23-3.53).Conclusion The patients with FIGO G3 grade and FIGO stage I endometrial cancer are more likely to develop POLE mutation,and the patients with FIGO G3 grade and Ⅱ-Ⅳ stage are more likely to develop high copy number variation.Clinicopathological features should be combined with molecular type to guide the prognosis and treatment of the patients.